Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1044520240870010052
Tuberculosis and Respiratory Diseases
2024 Volume.87 No. 1 p.52 ~ p.64
Human Pluripotent Stem Cell-Derived Alveolar Organoids: Cellular Heterogeneity and Maturity
Jung Ji-Hye

Yang Se-Ran
Kim Woo-Jin
Rhee Chin-Kook
Hong Seok-Ho
Abstract
Chronic respiratory diseases such as idiopathic pulmonary fibrosis, chronic obstructive functional features of in vivo alveolar tissue. In particular, the incorporation of immunecells such as macrophages into hPSC-AO systems is crucial for disease modeling andsubsequent drug screening. In this review, we summarize current methods for differentiatingalveolar epithelial cells from hPSCs followed by AO generation and their applicationsin disease modeling, drug testing, and toxicity evaluation. In addition, we reviewhow current hPSC-AOs closely resemble in vivo alveoli in terms of phenotype, cellularheterogeneity, and maturity.
pulmonary disease, and respiratory infections injure the alveoli; the damage evoked ismostly irreversible and occasionally leads to death. Achieving a detailed understandingof the pathogenesis of these fatal respiratory diseases has been hampered by limitedaccess to human alveolar tissue and the differences between mice and humans. Thus,the development of human alveolar organoid (AO) models that mimic in vivo physiologyand pathophysiology has gained tremendous attention over the last decade. In recentyears, human pluripotent stem cells (hPSCs) have been successfully employed togenerate several types of organoids representing different respiratory compartments,including alveolar regions. However, despite continued advances in three-dimensionalculture techniques and single-cell genomics, there is still a profound need to improvethe cellular heterogeneity and maturity of AOs to recapitulate the key histological and
KEYWORD
Alveolar Organoids, Human Pluripotent Stem Cells, Alveolar Epithelial Cells, Heterogeneity, Maturity
FullTexts / Linksout information
Listed journal information